Published in

Elsevier, Journal of Chromatography B, 20-21(877), p. 1805-1814

DOI: 10.1016/j.jchromb.2009.04.046

Links

Tools

Export citation

Search in Google Scholar

Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells.

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Red circle
Postprint: archiving forbidden
Red circle
Published version: archiving forbidden
Data provided by SHERPA/RoMEO

Abstract

This paper reports the validation of a liquid chromatography tandem mass spectrometry (LC-MS/MS) method that allows the quantification of 10 antiretroviral (ARV) drugs in peripheral blood mononuclear cells (PBMCs) using 6 different isotopic internal standards (IS) and its clinical application. PBMCs are isolated from blood by density gradient centrifugation and drugs are extracted with a 60% methanol (MeOH) solution containing the 6 IS. The cell extract is then injected in the HPLC system and analytes are separated on a Symmetry Shield RP18 2.1mmx50mm column. The different molecules are then detected by MS/MS in electrospray positive or negative ionisation modes and data are recorded using the multiple reaction monitoring (MRM) mode. Calibration curves are constructed in the range of 0.25-125ng/ml of cell extract by a 1/x(2) weighted quadratic regression. The regression coefficients obtained are always greater than 0.99 and back calculated values always comprised in the range of +/-15% from their nominal concentration. Mean extraction recoveries are greater than 80% for all analytes and the method is accurate and precise with CV and bias lower than 9.4%. The lower limits of quantification (LLOQ) of the different drugs range from 0.0125 to 0.2ng/ml of cell extract. This method was successfully applied to a cohort of 98 HIV-infected patients treated with Kaletra((R)) (400/100mg of lopinavir/ritonavir (LPV/RTV) twice a day, n=48) or with Stocrin((R)) (600mg once a day, n=50) and has been tested for cellular quantification of tipranavir (TPV) in 2 patients treated with Aptivus((R)) (500mg twice a day). The patients treated by Kaletra((R)) showed mean cell-associated concentrations (CC) of 1819.0 and 917.2ng/ml, for LPV and RTV, respectively. Patients treated with Stocrin((R)) showed mean CC of 2388.11ng/ml while both patients under Aptivus((R)) showed TPV CC of 4322.7 and 1078.0ng/ml, respectively. This method can be used to analyze ARV drug concentrations within the target tissue.